A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.

Manuel Hildago Rocio Garcia-Carbonero Kian-Huat LimWells A MessersmithIgnacio Garrido-Laguna Erkut Hasan Borazanci Andrew M Lowy Laura Medina Daniel A Laheru Beatriz Salvador-Barbero Marcos MalumbresDavid J ShieldsJoseph E Grossman Xin HuangMeggan TammaroJean-Francois MartiniYanke YuKenneth KernTeresa Macarulla

Published in: Cancer research communications (2022)

In this article, the combination of palbociclib, a CDK4/6 inhibitor, and nab-paclitaxel in advanced pancreatic cancer evaluates an important drug combination using translational science. In addition, the work presented combines preclinical and clinical data along with pharmacokinetic and pharmacodynamic assessments to find alternative treatments for this patient population.

Keyphrases

advanced non small cell lung cancer
public health
metastatic breast cancer
cell therapy
squamous cell carcinoma
electronic health record
case report
stem cells
big data
emergency department
adverse drug
machine learning
data analysis
chemotherapy induced
locally advanced